top of page
< Back

Clopidogrel

氯吡格雷

Mechanism of action:

Clopidogrel 是一種噻吩吡啶類(thienopyridine)的衍生物。Clopidogrel 本身為前驅藥,必須在肝臟中經由 CYP450 酵素(主要為 CYP2C19) 代謝成活性代謝物。活性代謝物會不可逆地抑制血小板上的 P2Y₁₂ 受體(P2Y₁₂ receptor),阻斷腺苷二磷酸(ADP)與該受體的結合,抑制下游的 GPIIb/IIIa 受體活化,使血小板無法交聯纖維蛋白原(fibrinogen),進而抑制血小板聚集。

​Reference(s):

1. Ganesan S et al. (2013). Clopidogrel variability: role of plasma protein binding alterations. Br J Clin Pharmacol. 


2. Mostafizar M et al. (2017). Characterization of binding sites of clopidogrel and interference of linoleic acid at the binding site on bovine serum albumin. Acta Pol Pharm. 


3. Zhang YJ et al. (2017). Pharmacokinetic and pharmacodynamic responses to clopidogrel: evidences and perspectives. Int J Environ Res Public Health.

bottom of page